SBIR/STTR Research Award

In situ single cell imaging

Award identifier cdfd201c8906dc45ae63427da2925f7cab725f6b36386e20eaf463d085b3e6a2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$216,126

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DOTQUANT LLC
Proposal award date
2019-05-01
Contract end date
2019-11-30
UEI
HPN4P84J65F7
Solicitation number
PA17-147
Topic code
102

Research abstract

Abstract Cancer immunotherapy is revolutionizing the landscape of cancer treatmentwith checkpoint inhibitorsactivated T cell therapiesand a range of other combinatorial approaches providing lasting benefits for patientsHoweverthe response rate to these advanced therapeutic approaches is onlydemonstrating the urgent need of better understanding of and eventually addressing the low response problemas well as the need of technologies for patient stratificationwhich often involves the use of biomarkers to fingerprint individualstumorsHerewe propose to develop a versatile quantum dotQdotbased single cell molecular profiling technology for in situ multiplexed quantitative molecular characterization of biological specimens with optical imaging resolutionDespite the availability of Qdots commercially since earlysthey have not received broad adoptions and enabled biological discoveriesalthough they offer much better optical properties than organic fluorophoresKey problems include the modest improvement in multiplexingand the sophisticatedlengthycost prohibitiveand low reproducibility probe preparation approaches developed to dateBased on a breakthrough made by ProfGao s labNatCommunthe technology proposed here is capable of solving both problemspatent recently awardedready for commercializationIt simultaneously achieves the multiplexing capability of mass spectrometryssand the sensitivityresolutionin situ imaginglow costgreat accessibilitymicroscopes are standard compared to mass spectrometersof immunofluorescence Narrative This project is aimed to develop and commercialize an innovative versatile quantum dot based imaging technology for highly multiplexedhigh resolutionin situ analysis of single cellsSuccess in producing such a powerful imaging tool will allow future collaborations and services for pharmaceutic companies to develop advanced immunotherapies and companion diagnostic kits

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

5 SBIR/STTR records share this UEI (2019–2024). Reported award amounts total $2,265,056. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.